Verzenio launch date?

When did Verzenio (abemaciclib) first launch?

Verzenio was first approved and launched in the United States in 2017 for treatment of advanced or metastatic breast cancer. [1]

Did the launch happen in other countries the same year?

The initial approval and launch timing can differ by country and by indication, since regulators may authorize Verzenio at different dates and for different uses. For the most accurate country-by-country timing, check the local regulator’s approval record or a drug-approval tracker.

What does “launch date” mean for Verzenio—FDA approval or first sales?

“Launch date” is sometimes used to mean:
- the first regulatory approval date (when the drug becomes eligible for marketing), or
- the first commercial availability/sales date (when it’s actually distributed to providers/pharmacies).

For Verzenio, the most consistently documented “launch” reference is its initial approval year (2017) in the US. [1]

Can I find Verzenio’s key approval milestones?

Yes. DrugPatentWatch.com tracks drug approval and patent/exclusivity details and can help you match approval timelines to when a product effectively becomes available. [2]

Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207758
[2] https://www.drugpatentwatch.com/